Header

UZH-Logo

Maintenance Infos

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results


Gallant, Joel E; Koenig, Ellen; Andrade-Villanueva, Jaime; Chetchotisakd, Ploenchan; DeJesus, Edwin; Antunes, Francisco; Arastéh, Keikawus; Moyle, Graeme; Rizzardini, Giuliano; Fehr, Jan; Liu, Yapei; Zhong, Lijie; Callebaut, Christian; Szwarcberg, Javier; Rhee, Martin S; Cheng, Andrew K (2013). Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. Journal of Infectious Diseases, 208(1):32-39.

Abstract

BACKGROUND:  Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro.
METHODS:  An international, randomized, double-blind, double-dummy, active-controlled trial was conducted to evaluate the efficacy and safety of COBI versus ritonavir (RTV) as a pharmacoenhancer of atazanavir (ATV) in combination with emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in treatment-naive patients. The primary end point was a human immunodeficiency virus type 1 (HIV-1) RNA load of <50 copies/mL at week 48 by the Food and Drug Administration snapshot algorithm; the noninferiority margin was 12%.
RESULTS:  A total of 692 patients were randomly assigned to a treatment arm and received study drug (344 in the COBI group vs 348 in the RTV group). At week 48, virologic success was achieved in 85% of COBI recipients and 87% of RTV recipients (difference, -2.2% [95% confidence interval, -7.4% to 3.0%]); among patients with a baseline HIV-1 RNA load of >100 000 copies/mL, rates were similar (86% vs 86%). Similar percentages of patients in both groups had serious adverse events (10% of COBI recipients vs 7% of RTV recipients) and adverse events leading to discontinuation of treatment with the study drug (7% vs 7%). Median increases in the serum creatinine level were 0.13 and 0.09 mg/dL, respectively, for COBI and RTV recipients.
CONCLUSIONS:  COBI was noninferior to RTV in combination with ATV plus FTC/TDF at week 48. Both regimens achieved high rates of virologic success. Safety and tolerability profiles of the 2 regimens were comparable. Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor ATV.

Abstract

BACKGROUND:  Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro.
METHODS:  An international, randomized, double-blind, double-dummy, active-controlled trial was conducted to evaluate the efficacy and safety of COBI versus ritonavir (RTV) as a pharmacoenhancer of atazanavir (ATV) in combination with emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in treatment-naive patients. The primary end point was a human immunodeficiency virus type 1 (HIV-1) RNA load of <50 copies/mL at week 48 by the Food and Drug Administration snapshot algorithm; the noninferiority margin was 12%.
RESULTS:  A total of 692 patients were randomly assigned to a treatment arm and received study drug (344 in the COBI group vs 348 in the RTV group). At week 48, virologic success was achieved in 85% of COBI recipients and 87% of RTV recipients (difference, -2.2% [95% confidence interval, -7.4% to 3.0%]); among patients with a baseline HIV-1 RNA load of >100 000 copies/mL, rates were similar (86% vs 86%). Similar percentages of patients in both groups had serious adverse events (10% of COBI recipients vs 7% of RTV recipients) and adverse events leading to discontinuation of treatment with the study drug (7% vs 7%). Median increases in the serum creatinine level were 0.13 and 0.09 mg/dL, respectively, for COBI and RTV recipients.
CONCLUSIONS:  COBI was noninferior to RTV in combination with ATV plus FTC/TDF at week 48. Both regimens achieved high rates of virologic success. Safety and tolerability profiles of the 2 regimens were comparable. Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor ATV.

Statistics

Citations

66 citations in Web of Science®
77 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

74 downloads since deposited on 03 Feb 2014
23 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Infectious Diseases
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2013
Deposited On:03 Feb 2014 15:34
Last Modified:13 Dec 2017 05:53
Publisher:Oxford University Press
ISSN:0022-1899
Additional Information:This is a pre-copy-editing, author-produced PDF of an article accepted for publication in the Journal of Infectious Diseases following peer review. The definitive publisher-authenticated version Gallant, Joel E; Koenig, Ellen; Andrade-Villanueva, Jaime; Chetchotisakd, Ploenchan; DeJesus, Edwin; Antunes, Francisco; Arastéh, Keikawus; Moyle, Graeme; Rizzardini, Giuliano; Fehr, Jan; Liu, Yapei; Zhong, Lijie; Callebaut, Christian; Szwarcberg, Javier; Rhee, Martin S; Cheng, Andrew K (2013). Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. Journal of Infectious Diseases, 208(1):32-39. is available online at: http://jid.oxfordjournals.org/content/208/1/32.
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1093/infdis/jit122
PubMed ID:23532097

Download

Download PDF  'Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 383kB
View at publisher